Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors
October 28 2021 - 8:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty
pharmaceutical company, today announced the appointment of Carmen
Volkart to its Board of Directors. Ms. Volkart will also serve as a
Member of the Audit Committee. Ms. Volkart is a seasoned medical
device executive with extensive finance and operations experience
at publicly traded and private companies.
Since 2018, she has served as the Chief
Financial Officer of NatureWorks, LLC. Prior to that, she was the
Chief Financial Officer at NxThera, Inc. From 2002 to 2012, she
also served as the Chief Financial Officer of Tornier, NV, Spine
Wave, Inc. and American Medical Systems, Inc. Additionally, she was
Vice President/GM of Musculoskeletal Tissue Services at Medtronic,
Inc. and started her career at Peat, Marwick, Mitchell & Co.
Ms. Volkart has public company board experience, which includes the
Memry Corporation, SonoSite, Inc. and Modular Medical, Inc. She is
a Certified Public Accountant and received her B.S. in Accounting
from the University of North Dakota and MBA from the University of
Minnesota, Carlson School of Management.
Leonard S. Jacob, M.D., Ph.D., Chairman of the
Board of Antares Pharma, commented, “We are delighted to welcome
another experienced healthcare executive to the Board of Directors.
With her extensive background in growing healthcare companies, we
believe Ms. Volkart’s contributions will prove beneficial across
our organization. We look forward to leveraging her successful
career as we continue to execute on our growth initiatives.”
Ms. Volkart commented, “I am delighted to join
the Board of Directors at Antares Pharma and support their efforts
as they continue to enhance their proprietary portfolio and partner
business. I believe my healthcare experiences will support the
overall growth strategy of the company. I appreciate the
opportunity to join Antares at this juncture.”
About Antares Pharma
Antares Pharma, Inc. is a specialty
pharmaceutical company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals
(AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s FDA-approved products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva. The Company also markets NOCDURNA®
(desmopressin acetate) in the U.S. and expects to commercially
launch TLANDO® (testosterone undecanoate) in the U.S. pending final
FDA approval.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the Company’s ability to achieve
the 2021 full-year revenue guidance; the uncertainty regarding the
ongoing COVID-19 pandemic, including new strains of the virus, and
the mitigation measures and other restrictions implemented in
response to the same and the impact on demand for our products, new
patients and prescriptions, future revenue, product supply,
clinical trials, and our overall business, operating results and
financial condition; commercial success
of XYOSTED® and
future revenue from the same; market acceptance of
Teva’s generic epinephrine auto-injector product and future revenue
from the same; future prescriptions and sales of
OTREXUP®; successful
commercialization of NOCDURNA® in
the U.S. and market acceptance and future revenue from the
same; uncertainties regarding future FDA approval
of TLANDO®, market acceptance and
future revenue from the same, whether Antares will exercise the
option for LPCN 1111 (TLANDO XR)
and if exercised, future timing and success of the clinical
development program for TLANDO XR
and future FDA approval, market acceptance and revenue from the
same; whether the FDA will withdraw marketing
approval for AMAG Pharmaceuticals’
Makena® subcutaneous auto
injector following the FDA letter seeking withdrawal, the outcome
of the FDA hearing and whether Makena®
will be successful and future
prescriptions, market acceptance and revenue from the same; Teva’s
ability to successfully commercialize
VIBEX® Sumatriptan Injection USP
and the amount of revenue from the same; Teva’s ability to
successfully commercialize generic teriparatide in Europe, Canada
and Israel and future revenue from the same, successful development
including the timing and results of the Phase 3 trial of the drug
device combination product for selatogrel with Idorsia
Pharmaceuticals and FDA and global regulatory approvals and future
revenue from the same; the timing and results of the clinical
development program for ATRS-1902 adrenal crisis rescue
auto-injector, future NDA submission and FDA approval of the same,
and if approved, future market acceptance and revenue for the same;
FDA approval of Teva’s ANDAs for both generic
Forteo® and
Byetta® and future revenue from
the same; the timing and results of the Company’s or its partners’
research projects or clinical trials of product candidates in
development including the Company’s urology
assets in development as well as Pfizer’s
undisclosed development product; actions by the FDA or other
regulatory agencies with respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to repay the debt obligation to Hercules Capital; the Company’s
ability to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:Tram BuiVice President,
Corporate Communications and Investor
Relations609-359-3016tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2023 to Apr 2024